Insight Molecular Diagnostics Inc. (IMDX)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Research and Development of Diagnostic Tests for The Detection of Cancer	4.05M	1.88M	1.50M	958.00K	2.20M
Research and Development of Diagnostic Tests for The Detection of Cancer Growth	115.58%	25.15%	56.89%	-56.41%	80.76%
Total	4.05M	1.88M	1.50M	958.00K	2.20M
Total Growth	115.58%	25.15%	56.89%	-56.41%	80.76%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States	4.03M	1.67M	916.83K	737.66K	1.00M
United States Growth	140.94%	82.48%	24.29%	-26.57%	35.42%
Europe	24.00K	18.00K	-	-	-
Europe Growth	33.33%	-	-	-	-
United Kingdom	-	45.00K	-	-	-
Asia-pacific	-	145.00K	-	-	-
Outside of The United States	-	-	586.17K	220.34K	1.24M
Outside of The United States Growth	-	-	166.03%	-82.18%	160.70%
Total	4.05M	1.88M	1.50M	958.00K	2.24M
Total Growth	115.58%	25.15%	56.89%	-57.25%	84.28%

Data Source: S&P Global Market Intelligence Last updated: Mar 26, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 9, 2026

Data Sources Report a data error